Clinical showdown in immuno-oncology
The latest edition of the PD(L)anner provides key updates and details upcoming global events in immuno-oncology.
Esmo 2022 – the new liver cancer entrants line up
Late-breakers give tislelizumab, camrelizumab and Keytruda outside chances to add to the first-line armamentarium.
Brace for an end-of-year boost to drug approvals
The first half of 2022 was slow on the regulatory front, but plenty of big decisions remain for Bristol Myers Squibb, Apellis and others.
Go or no go? Bristol’s Tyk2 test
A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
